本文關(guān)鍵詞：區(qū)域動(dòng)脈灌注化療栓塞聯(lián)合全身靜脈化療治療進(jìn)展期胃癌的臨床研究　出處：《現(xiàn)代消化及介入診療》2017年02期 　論文類型：期刊論文

  更多相關(guān)文章： 進(jìn)展期胃癌 動(dòng)脈灌注化療栓塞 靜脈化療

【摘要】：目的研究區(qū)域動(dòng)脈灌注化療栓塞聯(lián)合全身靜脈化療治療進(jìn)展期胃癌的臨床療效。方法選取我院2010年4月至2013年4月收治的82例進(jìn)展期胃癌患者為研究對(duì)象,隨機(jī)分為聯(lián)合化療組與靜脈化療組,每組41例。聯(lián)合化療組采用區(qū)域動(dòng)脈灌注栓塞聯(lián)合全身靜脈化療,靜脈化療組給予單純?nèi)盱o脈化療,比較兩組的臨床療效、腫瘤標(biāo)志物含量、毒性反應(yīng)以及生存率。結(jié)果聯(lián)合化療組的總緩解率、3年生存率分別為70.7%、68.3%,顯著高于靜脈化療組的48.8%、46.3%(P0.05);聯(lián)合化療組治療后的癌胚抗原(CEA)、糖鏈抗原72-4(CA72-4)、Ⅲ~Ⅴ度惡心嘔吐、Ⅲ~Ⅴ度白細(xì)胞減少發(fā)生率分別為(15.22±4.18)μg/L、(28.46±9.17)U/mL、12.2%、4.9%顯著低于靜脈化療組的(21.36±6.13)μg/L、(45.83±14.65)U/mL、31.7%、24.4%(P均0.05)。結(jié)論區(qū)域動(dòng)脈灌注化療栓塞聯(lián)合全身靜脈化療治療進(jìn)展期胃癌患者,可以提高化療藥物效果,殺滅腫瘤細(xì)胞,縮小腫瘤體積,且毒副反應(yīng)較小,患者耐受性好。
[Abstract]:Objective to study the clinical effect of regional arterial infusion chemoembolization combined with systemic intravenous chemotherapy in the treatment of advanced gastric cancer. Methods 82 patients with advanced gastric cancer from April 2010 to April 2013 in our hospital were selected. The subject of the study. The patients were randomly divided into combined chemotherapy group (n = 41) and intravenous chemotherapy group (n = 41). The combined chemotherapy group was treated with regional arterial infusion embolization combined with systemic intravenous chemotherapy, and the intravenous chemotherapy group was treated with simple systemic intravenous chemotherapy. Results the total remission rate and 3-year survival rate of the combined chemotherapy group were 70.7% and 68.3% respectively. It was significantly higher than that in intravenous chemotherapy group (48.8%) and 46.3% (P 0.05). The carcinoembryonic antigen (CEA), carbohydrate antigen (72-4) and CA72-4 (鈪，

本文編號(hào)：1412498